Clinical Trial Update: Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease

View source ↗

Summary

Amgen's expanded access protocol for Teprotumumab (HZN-001) to treat active thyroid eye disease (Graves' orbitopathy) has been updated; the program is associate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Orbitopathy
• Thyroid Eye Disease

Drugs mentioned

• Teprotumumab (teprotumumab)

Snippet

Sponsor: Amgen | Conditions: Thyroid Eye Disease, Graves' Orbitopathy | Status: APPROVED_FOR_MARKETING